| Hsu WM |
------>authors3_c= ------>paper_class1=2 ------>Impact_Factor=None ------>paper_class3=0 ------>paper_class2=0 ------>vol=31 ------>confirm_bywho=wmhsu ------>insert_bywho=wmhsu ------>Jurnal_Rank=None ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=99 ------>medlineContent= ------>unit=E0115 ------>insert_date=20081220 ------>iam=1 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c=??? ------>score=33 ------>journal_name=World Ophthalmology Congress ------>paper_name=Epidemiology of eyelid cancers ------>confirm_date=20081224 ------>tch_id=096076 ------>pmid=19667336 ------>page1=99 ------>fullAbstract=OBJECTIVE: To determine the primary sites, clinical features, treatment, and outcome of 20 patients with cancer metastatic to the eyelids. METHODS: Retrospective review of medical records. RESULTS: The primary tumors included skin melanoma (4 [20%]), uveal melanoma (4 [20%]), breast carcinoma and conjunctival melanoma (3 [15%] each), renal cell carcinoma (2 [10%]), and medullary thyroid carcinoma, prostate carcinoma, lung carcinoma, and salivary gland carcinoma (1 [5%] each). Eyelid metastasis was the first sign of systemic cancer in 3 patients (15%). The most common clinical finding at the initial examination was a solitary nodule in 12 patients (60%), a flat pigmented lesion and diffuse eyelid swelling in 3 patients each (15%), and multiple nodules and epiphora in 1 patient (5%) each. Ten patients (50%) had concomitant ocular site metastasis. Primary treatment included excision alone in 6 patients (30%), external beam radiotherapy in 7 (35%), systemic chemotherapy in 4 (20%), and observation in 3 (15%). The metastatic tumors regressed in 10 patients (50%), remained stable in 7 (35%), and showed progression in 3 (15%). After a mean follow-up of 16 months, 9 patients (45%) were alive and 11 (55%) had died of systemic metastatic disease. CONCLUSIONS: Eyelid metastasis can display a variety of clinical features and should be considered in patients with known systemic cancer. These patients usually have multiple metastatic sites, ocular and nonocular. The systemic prognosis is poor. ------>tmu_sno=None ------>sno=20894 ------>authors2= ------>authors3= ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Hsu WM ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=2 ------>updateTitle=Metastatic tumors to the eyelid: report of 20 cases and review of the literature. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=NULL ------>no=progra ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2008 ------>submit_flag=None ------>publish_month=6 |